KYMR Stock Analysis: Kymera Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 10.891m USD | 12M Return: 89.6% | US5015751044 | Charts, Fundamentals & Technical Analysis

STAT6 Degrader, IRF5 Degrader, IRAK4 Inhibitor, CDK2 Inhibitor
Total Rating 38
Safety 57
Buy Signal 0.13
Biotechnology
Sub-Industry Rotation: +4.6
Market Cap: 10.9B
Avg Turnover: 116M
Risk 3d forecast
Volatility58.2%
VaR 5th Pctl9.64%
VaR vs Median0.54%
Reward TTM
Sharpe Ratio1.24
Rel. Str. IBD94.2
Rel. Str. Peer Group84.3 pctl
Character TTM
Beta1.164
Beta Downside0.612
Hurst Exponent0.556
Choppyness50.3%
Drawdowns 3y
Max DD59.83%
CAGR/Max DD1.45
CAGR/Mean DD6.13
EPS (Earnings per Share) EPS (Earnings per Share) of KYMR over the last years for every Quarter: "2021-09": -0.56, "2021-12": -0.66, "2022-03": -0.71, "2022-06": -0.78, "2022-09": -0.79, "2022-12": -0.6, "2023-03": -0.7, "2023-06": -0.67, "2023-09": -0.9, "2023-12": -0.25, "2024-03": -0.62, "2024-06": -0.58, "2024-09": -0.82, "2024-12": -0.89, "2025-03": -0.82, "2025-06": -0.95, "2025-09": -0.94, "2025-12": -0.97, "2026-03": -0.71, "2026-06": -0.62, "2026-09": -1.32,
Last SUE: -0.47
Qual. Beats: 0
Revenue Revenue of KYMR over the last years for every Quarter: 2021-09: 20.336, 2021-12: 15.275, 2022-03: 9.622, 2022-06: 11.514, 2022-09: 9.551, 2022-12: 16.139, 2023-03: 9.466, 2023-06: 16.513, 2023-09: 4.728, 2023-12: 47.885, 2024-03: 10.287, 2024-06: 25.65, 2024-09: 3.741, 2024-12: 7.394, 2025-03: 22.1, 2025-06: 11.476, 2025-09: 2.764, 2025-12: 2.86, 2026-03: 34.365, 2026-06: 65, 2026-09: 0,
Rev. CAGR: -3.99%
Rev. Trend: -10.2%
Last SUE: -0.15
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Below Avwap Earnings

Tailwinds

Rs Leader
Idiosyncratic Leader

Seasonality 6.2 years of data, until 10/2026

Jan -2.0% 0
Feb -6.8% 5
Mar -9.0% 5
Apr +3.2% 0
May -4.2% 5
Jun +16.0% 5
Jul +6.1% 5
Aug +5.5% 5
Sep -7.4% 11
Oct +4.4% 0
Nov +4.3% 5
Dec +13.3% 5

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: KYMR Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs that selectively degrade disease-causing proteins using the bodys natural protein degradation system, an approach known as targeted protein degradation. The company is headquartered in Watertown, Massachusetts, was incorporated in 2015, and trades on NASDAQ under the ticker KYMR.

The pipeline is built around several oral degrader programs. KT-621, an oral STAT6 degrader, is in Phase 2b trials for atopic dermatitis, asthma, COPD, and related conditions. KT-579, an oral IRF5 degrader, is in Phase 1 development for autoimmune diseases such as lupus, rheumatoid arthritis, and inflammatory bowel disease. The IRAK4 program (KT-485/SAR447971) is in Phase II for immunology-inflammation indications including hidradenitis suppurativa and atopic dermatitis, and is partnered with Sanofi S.A. outside the oncology and immuno-oncology fields. A separate CDK2 program targets oncology indications such as breast cancer and other solid tumors.

As a clinical-stage biotech without approved products, Kymeras business model relies on advancing candidates through trials and monetizing programs through partnerships, as illustrated by the Sanofi alliance. Its placement in the biotechnology sub-industry reflects a focus on platform-based drug discovery rather than commercial product sales, with the targeted protein degradation modality representing a relatively new class of therapeutics distinct from traditional small molecule inhibitors.

Headlines to Watch Out For
  • KT-621 Phase 2b atopic dermatitis data readout approaches
  • Sanofi IRAK4 partnership milestones validate pipeline and extend cash runway
  • Rising R&D spending pressures cash position and operating margins
Piotroski VR-10 (Strict) 0.0
Net Income: -349.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.16 > 0.02 and ΔFCF/TA 4.54 > 1.0
NWC/Revenue: 889.1% < 20% (prev 1.04k%; Δ -155.2% < -1%)
CFO/TA -0.16 > 3% & CFO -287.6m > Net Income -349.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 11.13 > 1.5 & < 3
Outstanding Shares: last quarter (100.1m) vs 12m ago 14.66% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 7.13% > 50% (prev 3.97%; Δ 3.16% > 0%)
Interest Coverage Ratio: -1.28k > 6 (EBIT TTM -349.4m / Interest Expense TTM 273k)
Altman Z'' 10.00
A: 0.51 (Total Current Assets 998.6m - Total Current Liabilities 89.7m) / Total Assets 1.77b
B: -0.75 (Retained Earnings -1.33b / Total Assets 1.77b)
C: -0.24 (EBIT TTM -349.4m / Avg Total Assets 1.43b)
D: 10.57 (Book Value of Equity 1.61b / Total Liabilities 152.7m)
Altman-Z'' = 10.39 = AAA
What is the price of KYMR shares?

As of November 18, 2026, the stock is trading at USD 121.52 with a total of 855,147 shares traded. Over the past week, the price has changed by -11.07%, over one month by +12.45%, over three months by +0.09% and over the past year by +89.58%.

Current recommended Stop Loss: 113.20 (which is 6.8% or 1.3 ATR below the current price).

Is KYMR a buy, sell or hold?

Kymera Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy KYMR.

  • StrongBuy: 17
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KYMR price?
Analysts Target Price 145.2 19.5%
Kymera Therapeutics (KYMR) - Fundamental Data Overview as of 17 November 2026
Market Cap USD = 10.9b (10.9b USD * 1.0 USD.USD)
P/S = 106.5274
P/B = 6.7484
Revenue TTM = 102.2m USD
EBIT TTM = -349.4m USD
EBITDA TTM = -341.3m USD
Long Term Debt = 63.0m USD (estimated: total debt 76.6m - short term 13.6m)
Short Term Debt = 13.6m USD (from shortTermDebt, last quarter)
Debt = 76.6m USD (from shortLongTermDebtTotal, last quarter) (leases 76.6m already included)
Net Debt = -894.6m USD (calculated: Debt 76.6m - CCE 971.2m)
Enterprise Value = 10.00b USD (10.9b + Debt 76.6m - CCE 971.2m)
Interest Coverage Ratio = -1.28k (Ebit TTM -349.4m / Interest Expense TTM 273k)
EV/FCF = -34.60x (Enterprise Value 10.00b / FCF TTM -288.9m)
FCF Yield = -2.89% (FCF TTM -288.9m / Enterprise Value 10.00b)
 FCF Margin = -282.6% (FCF TTM -288.9m / Revenue TTM 102.2m)
 Net Margin = -341.9% (Net Income TTM -349.5m / Revenue TTM 102.2m)
 Gross Margin = unknown ((Revenue TTM 102.2m - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 5.66 (Enterprise Value 10.00b / Total Assets 1.77b)
Interest Expense / Debt = 0.36% (Interest Expense 273k / Debt 76.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -276.0m (EBIT -349.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.13 (Total Current Assets 998.6m / Total Current Liabilities 89.7m)
Debt / Equity = 0.05 (Debt 76.6m / totalStockholderEquity, last quarter 1.61b)
 Debt / EBITDA = 2.62 (negative EBITDA) (Net Debt -894.6m / EBITDA -341.3m)
 Debt / FCF = 3.10 (negative FCF - burning cash) (Net Debt -894.6m / FCF TTM -288.9m)
 Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = -24.36% (Net Income -349.5m / Total Assets 1.77b)
RoE = -22.39% (Net Income TTM -349.5m / Total Stockholder Equity 1.56b)
RoCE = -21.52% (EBIT -349.4m / Capital Employed (Equity 1.56b + L.T.Debt 63.0m))
 RoIC = -16.37% (negative operating profit) (NOPAT -276.0m / Invested Capital 1.69b)
 WACC = 9.49% (E(10.9b)/V(11.0b) * Re(9.55%) + D(76.6m)/V(11.0b) * Rd(0.36%) * (1-Tc(0.21)))
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.37 | Cagr: 15.02%
 [DCF] Fair Price = unknown (Cash Flow -288.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.47 | # QB: 0
Revenue Correlation: -10.22 | Revenue CAGR: -3.99% | SUE: -0.15 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-1.35 | Chg30d=+0.86% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-3.93 | Chg30d=-2.29% | Revisions=-46% | GrowthEPS=-6.4% | GrowthRev=+153.5%
EPS next Year (2027-12-31): EPS=-5.12 | Chg30d=-0.37% | Revisions=-13% | GrowthEPS=-30.3% | GrowthRev=-57.7%
[Analyst] Revisions Ratio: -30% (up=8, down=16)